Compare · GILD vs MGTX
GILD vs MGTX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and MeiraGTx Holdings plc (MGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MGTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 128.7x MGTX ($1.43B).
- Over the past year, GILD is up 29.7% and MGTX is up 98.7% - MGTX leads by 69.0 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 8 for MGTX).
- GILD has more recent analyst coverage (25 ratings vs 3 for MGTX).
- Company
- Gilead Sciences Inc.
- MeiraGTx Holdings plc
- Price
- $148.78+1.33%
- $14.90+0.51%
- Market cap
- $184.47B
- $1.43B
- 1M return
- +13.98%
- +21.28%
- 1Y return
- +29.69%
- +98.73%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 3
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest MGTX
- PRESIDENT & CEO Forbes Alexandria sold $859,320 worth of Ordinary Shares (62,000 units at $13.86) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,325,695 units (SEC Form 4)
- SEC Form 144 filed by MeiraGTx Holdings plc
- SEC Form S-8 filed by MeiraGTx Holdings plc
- SEC Form 10-Q filed by MeiraGTx Holdings plc
- MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
- Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
- MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CFO & COO Giroux Richard sold $700,560 worth of Ordinary Shares (56,000 units at $12.51) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 908,530 units (SEC Form 4)
- CHIEF SCI OFCR, OPHTHALMOLOGY Naylor Stuart sold $409,470 worth of Ordinary Shares (27,659 units at $14.80) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 640,846 units (SEC Form 4)